The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells by Giannuzzo, Andrea et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal
adenocarcinoma cells
Giannuzzo, Andrea; Pedersen, Stine Helene Falsig; Novak, Ivana
Published in:
Molecular Cancer
DOI:
10.1186/s12943-015-0472-4
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Giannuzzo, A., Pedersen, S. H. F., & Novak, I. (2015). The P2X7 receptor regulates cell survival, migration and
invasion of pancreatic ductal adenocarcinoma cells. Molecular Cancer, 14, [203].
https://doi.org/10.1186/s12943-015-0472-4
Download date: 03. Feb. 2020
RESEARCH Open Access
The P2X7 receptor regulates cell survival,
migration and invasion of pancreatic ductal
adenocarcinoma cells
Andrea Giannuzzo, Stine Falsig Pedersen and Ivana Novak*
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is presently one of the cancers with the worst survival
rates and least effective treatments. Moreover, total deaths due to PDAC are predicted to increase in the next
15 years. Therefore, novel insights into basic mechanism of PDAC development and therapies are needed. PDAC is
characterized by a complex microenvironment, in which cancer and stromal cells release different molecules, such
as ATP. ATP can be transported and/or exocytosed from active cancer cells and released from dying cells in the
necrotic core of the cancer. We hypothesized that one of the ATP receptors, the P2X7 receptor (P2X7R) could be
an important player in PDAC behaviour.
Methods: We determined the expression (real time PCR and Western blot) and localization (immunofluorescence)
of P2X7R in human PDAC cell lines (AsPC-1, BxPC-3, Capan-1, MiaPaCa-2, Panc-1) and a “normal” human pancreatic
duct epithelial cell line (HPDE). The function of P2X7R in proliferation (BrdU assay), migration (wound assay) and
invasion (Boyden chamber with matrigel) was characterized. Furthermore, we studied P2X7R-dependent pore
formation (YoPro-1 assay) and cell death (caspase and annexin V / propidium iodide assays).
Results: We found higher expression of P2X7R protein in PDAC compared to HPDE cells. P2X7R had notable
disparate effects on PDAC survival. Firstly, high concentrations of ATP or the specific P2X7R agonist, BzATP, had
cytotoxic effects in all cell lines, and cell death was mediated by necrosis. Moreover, the P2X7R–pore antagonist,
A438079, prevented ATP-induced pore formation and cell death. Second, in basal conditions and with low
concentrations of ATP/BzATP, the P2X7R allosteric inhibitor AZ10606120 reduced proliferation in all PDAC cell
lines. P2X7R also affected other key characteristics of cancer cell behavior. AZ10606120 reduced cell migration
and invasion in PDAC cell lines compared to that of untreated/vehicle-treated control cells, and stimulation with
sub-millimolar concentrations of ATP or BzATP substantially increased cell invasion.
Conclusions: PDAC cell lines overexpress P2X7R and the receptor plays crucial roles in cell survival, migration and
invasion. Therefore, we propose that drugs targeting P2X7R could be exploited in therapy of pancreatic cancer.
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Background
Pancreatic Ductal Adenocarcinoma (PDAC) is an ag-
gressive and devastating disease [1]. The estimated 5-
year survival rate is less than 5 %, even in regions of
the world with the best healthcare, and incidence is
expected to rise with ageing population [2]. In USA,
total deaths due to pancreatic cancer (where PDAC
constitute about 90 % of these cancers), are projected
to increase dramatically and become the second lead-
ing cause of cancer-related deaths before 2030 [3].
Due to redundancy of pancreatic function, the disease
is detected relatively late, when the local tumor has
advanced or the disease has disseminated. Most con-
ventional chemotherapies fail to give substantial re-
sponses in PDAC and one of the important factors
may be the unusual and impermeable tumor micro-
environment (TME). PDAC is a solid tumor rich in
stromal cells and exhibiting marked desmoplasia, stiff-
ness and poor vascularization [4]. The cellular com-
partment of TME includes, apart from cancer cells,
pancreatic stellate cells (PSCs), cancer associated fi-
broblasts, various immune cells, endothelial cells and
pericytes. The acellular component includes, extracel-
lular matrix (ECM) components and matrix-degrading
enzymes, as well as a number of growth factors and
cytokines [4], autocrine/paracrine factors, metabolites
and ions. In the complex TME, cancer and stromal
cells release a variety of molecules that can support
tumor proliferation, migration, invasion and immune
system escape [5]. One relevant and multifunctional
candidate is ATP, which can be released from metabol-
ically active cancer cells and other cells to the extra-
cellular space via plasma membrane transport systems
or by exocytosis, and from dying cells in the tumor
necrotic area [6]. It is difficult to detect intra-tumor
ATP levels due to up-regulated ecto-nucleotidases and
hydrolysis of ATP to adenosine [7]. Using plasma
membrane luciferase and bioluminescence detection,
it has been possible to detect extracellular ATP at
hundreds micromolar concentration in tumor intersti-
tium in melanoma and ovarian cancer [8]. However,
methods to monitor ATP concentration gradients
across tissues or tumors are not yet available.
ATP and other extracellular nucleotides activate two
families of receptors: P2X receptors, a family of ligand-
gated receptor channels; and P2Y receptors, G protein-
coupled receptors [9]. One of the most remarkable pur-
inergic receptors is the P2X7 receptor, because it has a
crucial role in several physiological and pathophysio-
logical processes and because the receptor is highly
polymorphic, and single nucleotide polymorphism
(SNPs) are associated with several diseases including
central nervous system diseases, pain, osteoporosis,
cancer and inflammation [10]. There are nine different
human splice variants - named P2X7A–J (P2X7B, P2X7C,
P2X7E, P2X7G and P2X7J lack of C-terminal) [10], and
isoforms A and B are the most studied. P2X7 receptor
(P2X7R) is a two membrane-spanning domain protein
that forms trimers and at submillimolar extracellular
ATP concentrations behaves as a cation channel and
elicits a number of cellular responses. An extensively
documented and well established role of the receptor is
in cell death. At millimolar ATP concentrations P2X7R
mediates plasma membrane permeabilization, due to
formation of pores permeable to large molecules (up to
900 Da) [11, 12], and this leads to apoptotic/necrotic
events [13, 14]. Recently, several reports showed a
novel characteristic of P2X7R, namely that it can in-
crease cell proliferation [15, 16]. This effect may be
elicited at basal or low ATP concentrations [17, 18]
and/or depends on isoforms expression [19].
The P2X7 receptor is over-expressed in many cancer
types [20–22], and potentially the unusual double role of
P2X7R in cancer cell proliferation and cell death and
modulation by immune system could find applications
in cancer therapy. Two hypotheses regarding the roles of
P2X7R are proposed: either the receptor can be consid-
ered as an anti-tumor protein inducing cell death in can-
cer cells [23–25]; or the receptor is a pro-cancerous
protein increasing tumor growth and invasion [26, 27].
Given that the TME is likely to exhibit ATP concentra-
tion gradients, the receptor could serve different func-
tions in different locations in the tumor [6].
In pancreas, P2X7R is expressed in rodent duct
cells (but not acinar cells) and in human PDAC cells
grown as epithelial monolayers, and in both the re-
ceptor has a role in calcium signaling and regulation
of ion transport and secretion [28–30]. Moreover,
P2X7R is expressed in pancreatic stellate cells (PSCs)
[31], which are the major contributors to the abun-
dant stromal/desmoplastic reaction that characterizes
pancreatic cancer [32]. The role of P2X7R in PSCs is
to support proliferation and/or cell death depending
on extracellular ATP concentrations [17]. One study
utilizing patient tissues reported that there was a ten-
dencial increase of P2X7R protein level in chronic
pancreatitis and pancreatic cancer compared to nor-
mal tissues [33].
In light of the fact that this receptor is important for
cell survival and may be overexpressed in pancreatic
cancer, we need to understand its role in PDAC behav-
ior. The aim of this study was to use a simple in vitro
cell model to detect the expression of P2X7R in PDAC
cell lines and to clarify whether it affects PDAC behavior
such as cell proliferation, cell death, migration and inva-
sion. Knowledge gained from this study can form the
basis for more advanced drug testing in in vivo pancreas
cancer models.
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Results
Expression and localization of P2X7 receptor in PDAC and
control human pancreatic duct cell lines
Five PDAC cell lines were used: AsPC-1, BxPC-3,
Capan-1, MiaPaCa-2 and Panc-1. They are genotypically
and phenotypically heterogeneous and they are represen-
tative of different stages of pancreatic cancer. For ex-
ample, Panc-1 is derived from epithelioid pancreatic
carcinoma, MiaPaCa-2 is a poorly differentiated cell line
[34], Capan-1 is a well differentiated cell line derived
from liver metastasis [35], and AsPC-1 is a poorly differ-
entiated cell line derived from nude mouse xenografts
initiated with cells from the ascites of a patient with
pancreatic cancer [36]. All cell lines have mutations in
TP53 and KRAS genes, except for BxPC-3 which has
wild type KRAS. HPDE, human “normal” pancreatic duct
epithelial cell line, transformed using HPV16-E6E7 [37]
was used as control.
The primer set for P2X7 detection (284 bp) (Table 1)
was designed such that the expression of the isoforms A
and B (and also G, H, J, D) would be detected in a real
time PCR. The forward primer would recognize the
junction between exon 3 and 4, and the reverse primer
the junction between the exon 6 and 7. The P2X7R ex-
pression among the different cell lines was normalized
with respect to HPDE, after normalization of each cell
line to average expression of QARS, GUSZ and β-actin
housekeeping genes. Figure 1a shows that compared to
HPDE cells, there was a significant down-regulation of
P2X7R transcripts in all the PDAC cell lines, except for
Capan-1 cells. In addition to P2X7R, pancreatic duct
cells also express a number of other P2X and P2Y recep-
tors and additional data for the key receptors transcripts
are given in Additional file 1: Figure S1 and primers are
in Additional file 2: Table S1.
Protein expression of the full length P2X7R A isoform
and the C-terminus truncated B isoform was determined
using Western blot and immunolocalization (Fig. 1b-c).
Figure 1b shows two bands, often seen by other re-
searchers, and the lower band may correspond to the iso-
form H. The band at 70 kDa, corresponding to the isoform
A, appears more abundant in all PDAC cell lines compared
to control HPDE cells, but significant increase is detected
only for Capan-1 and Panc-1. Figure 1c shows that there
was a slightly reduced, but not significant, expression of
the 42 kDa band that possibly corresponds to the isoform
B in AsPC-1, BxPC-3 and Panc-1; and there is significantly
lower expression in MiaPaCa-2 compared to HPDE cells.
Localization of P2X7R was detected by immunofluores-
cence and confocal microscopy and the results are shown
in Fig. 2. The immunofluorescence was observed in HPDE
and Panc-1 cells and the immunofluorescence signal
resulting from the polyclonal antibody recognizing the
extracellular loop, hence the A and B and potentially other
isoforms, was localized to the plasma membrane, and
weakly also in the cytoplasmic compartment (Fig. 2).
P2X7R affects cell proliferation and cell death
In the following series of experiments we investigated
the effect of a sustained activation or inhibition of P2X7
receptor on cell proliferation and/or death using BrdU
assay. First, cells were incubated with different concen-
trations of ATP and the results for the six cell lines are
shown in Fig. 3 (black symbols). Generally, with increas-
ing ATP concentration from 100 μM to 5 mM all cell
lines showed a decrease in BrdU incorporation, possibly
indicating cell death (see below). Minor deviations in re-
sponses were observed in Panc-1 cells, which were rela-
tively insensitive to 100 μM ATP, and in Capan-1 cells,
which showed an increase in BrdU incorporation with
5 mM ATP, but a reduction at 1 mM. This effect in
Capan-1 cells could be due to a selection of resistant
cells after long incubation with a high dose of ATP, as
shown in murine macrophage RAW 264.7 cells [38].
Lower concentrations of ATP (0.5–10 μM) had small
and inconsistent effects on BrdU incorporation, showing
a tendency of about 10–20 % increase in BrdU incorpor-
ation (Additional file 3: Figure S2).
In order to verify that the above described effects of ATP
were due to P2X7R, a more specific agonist, BzATP, was
used and the results are shown in Fig. 4. The application of
BzATP at 10 μM had no significant effects on all cell lines.
Table 1 Primers used for RT-PCR and Real Time PCR on PDACs and HPDE
Primers Accession numbers Sequence Product length
P2X7 FW [GenBank: GQ180122.1] CGGTTGTGTCCCGAGTATCC 284 bp
P2X7 RW CCTGGCAGGATGTTTCTCGT
β actin FW [GenBank: BC014861.1] GTGACATTAAGGAGAAGCTGTGC 300 bp
β actin RW CAATGCCAGGGTACATGGTG
GUSB FW [GenBank: M15182.1] ACTGACACCTCCAAGTATCCCA 200 bp
GUSB RW AACAGGTTACTGCCCTTGACAG
QARS FW [GenBank: BC000394.2] CCTCTATGAGCGACTATTCCAGC 200 bp
QARS RW GATGGCTGTCTGGATCCACG
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With an increase of the concentration of BzATP to
100 μM, a significant reduction of BrdU incorporation was
detected in HPDE, AsPC-1 (around 65 %) and BxPC-3
(around 30 %) cells. At high concentration of BzATP
(1 mM), all the cell lines showed a significant decrease in
BrdU incorporation (between 65 % and 85 %).
In the next series of experiments we tested the effects
of P2X7R inhibitors: the allosteric inhibitor AZ10606120
(10 μM) that affects cell proliferation; the competitive
antagonist A438079 (10 μM) that inhibits pore forma-
tion; and the non-competitive antagonist KN-62 (100
nM) that also inhibits CaM Kinase II [24, 27, 39–41].
Experiments where AZ10606120 was given without ex-
ogenous ATP (i.e. basal conditions) resulted in decreased
BrdU incorporation in all cell lines, with the largest de-
crease in Panc-1 and the lowest decrease in HPDE and
Capan-1 cells (Fig. 3, colored symbols). This would indi-
cate either that the inhibitor attenuated proliferation or
that it was cytotoxic and promoted cell death. We ex-
cluded the cytotoxic effect of the inhibitor with a Trypan
blue assay (Additional file 4: Figure S3). Therefore, the
inhibitory effect of AZ10606120 in basal conditions was
most likely related to a decrease in proliferation. Fur-
thermore, the inhibitor in combination with added
ATP concentrations (0.1–1.0 mM), resulted in a fur-
ther reduction of BrdU incorporation in all PDAC cell
lines. Accepting that the inhibitor is not cytotoxic, we
presume it reduced BrdU incorporation because it
inhibited cell proliferation, as also seen in other cells
[17, 27, 41]. At about 5 mM ATP effects of the inhibi-
tor were the smallest, indicating that cell death out-
weighted cell proliferation. Thus Fig. 3 shows two
effects on BrdU incorporation in a population of cell-
s—increasing ATP concentration causing cell death
(see below) and AZ10606120 causing a decrease in cell
proliferation. Interestingly, AZ10606120 was ineffect-
ive in HPDE cells treated with 0.1–5 mM exogenous
ATP, indicating that in these conditions cell death was
the predominant P2X7R response in these non-cancer
cells. In addition to AZ10606120, we also studied the
long-term effect of two other P2X7R inhibitors, the
pore-inhibitor A438079 and KN-62, and the results are
shown in Fig. 5. It appears that these inhibitors im-
proved BrdU incorporation if cells were stimulated
A B C
Fig. 1 Expression of P2X7R in PDACs and HPDE cells. a. Real time PCR and RT-PCR analysis of P2X7R expression in HPDE and PDAC cells. Insert shows a
representative gel of P2X7R mRNA (284 bp) in Panc-1. The data were normalized with respect to the three housekeeping genes: β-actin, β glucuronidase
(GUSB) and glutaminyl-tRNA synthetase (QARS) and expression in HPDE was set to 1. The bargraph shows data for four experiments (mean ± SEM). The
relative amount of mRNA was calculated from a standard curve run on each plate. b. Western blot band at around 70 kDa corresponding to the isoform
A [PR: Q99572-1], as shown on the insert. Loading control was β-actin [PR: P60709] detected at 42 kDa. All lanes were loaded with 50 μg of
proteins. c. Western blot band at around 42 kDa most likely corresponds to the isoform B [PR: Q99572-2]. The results were normalized with β-actin
that was used as a loading control. The graphs for the two isoforms show data of three experiments (mean ± SEM). Significant differences of expression
in PDAC in comparison to HPDE cells P < 0.05 (*) and P < 0.001 (**) are indicated
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with 0.1–1 mM ATP. Thus these inhibitors protected
cells against cell death until exogenous concentrations
of ATP were 5 mM.
The above data (Figs. 3, 4 and 5) indicated that high
concentrations of ATP and BzATP could lead to cell
death. We next investigated whether this was due to
apoptosis or necrosis. To detect induction of apoptotic
pathways, caspase 3/7 assay was used and data are
shown in Fig. 6a. The administration of 1 mM ATP
(20 h) had no significant effect on caspase 3/7 activation
in Panc-1 cells. We moreover did not detect any effect
when AZ10606120 was included alone or with 1 mM
ATP. As a positive control, it is shown that apoptosis in-
ducer AT101 (see methods) caused marked caspase
activation.
In addition to caspase 3/7 assay, an Annexin V-488/
propidium iodide (PI) assay was performed (Fig. 6b).
Panc-1 cells were incubated with 1 mM ATP (20 h) and
images in Fig. 6b show that a number of cells had red
nuclei (PI), indicating that the cell membrane was
permeabilized as in cells undergoing necrosis, and green
Annexin V, indicating phosphatidyl serine exposure on
cell surface. The transmission image also shows dis-
rupted cells with uneven surface and nuclear swelling,
also indicating a necrotic type of death.
Fig. 3 Effect of ATP and AZ10606120 on BrdU incorporation in PDACs and HPDE cells. Data for each cell line are given in one panel and filled
black symbols show the effect of different concentrations of added (exogenous) ATP (100 μM, 1 mM and 5 mM), or control (no exogenous ATP
added), on BrdU incorporation in all cell lines after 60 h. The colored symbols show the effect of ATP and control in combination with the allosteric
inhibitor AZ10606120 (10 μM), which was added 1 h before ATP. The results were normalized to 1 % serum control (100). The graphs show data from
three to six experiments (mean ± SEM); where each run was carried out in triplicates. Significant differences P < 0.05 (*, #) and P < 0.001 (**) from the
respective 1 % serum control (*, **) and with/without inhibitor (#) are indicated
Fig. 2 Immunolocalization of P2X7R in PDACs and HPDE cells. HPDE
and Panc-1 cells were grown on coverslips. P2X7R was stained with
a polyclonal antibody against the extracellular domain and Alexa
Fluor 568 (red) and DAPI was used to stain the nucleus (blue). All
bars are 25 μm
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P2X7R inhibitors have small effect on pore formation
One of the hallmarks of P2X7R is the ability to form
pores permeable to larger molecules up to 900 Da, as
shown in the above experiments. Therefore, we investi-
gated effect of high ATP concentration (5 mM) on
membrane permeabilization using YoPro-1 dye in a
physiological buffer and results are shown in Fig. 7.
The cell lines tested showed an increase in YoPro-1
uptake after stimulation with 5 mM ATP. The max-
imum YoPro-1 uptake with 5 mM ATP was detected
after 20 min in AsPC-1 and Panc-1 cells, and after 50–
60 min in BxPC-3 cells. We tried to inhibit P2X7R and
P2X7R-mediated pore formation using two inhibitors:
the allosteric inhibitor of P2X7R AZ10606120 (10 μM);
and the competitive antagonist A438079 (10 μM), the
latter known as the pore inhibitor. All cell lines tested
showed a small but significant reduction in pore for-
mation when A438079 was used: for YoPro-1 uptake at
60 min, this inhibition was around 6 % in BxPC-3,
13 % in AsPC-1 and 4.5 % in Panc-1 cells. A438079
protected Panc-1 cells from pore-formation in the
short-term experiment (Fig. 7) and from cell death in
long-term experiment where BrdU incorporation was
monitored (Fig. 5). The allosteric inhibitor, AZ10606120,
had no significant effect on YoPro-1 uptake in Panc-1
and AsPC-1 cells and showed a small inhibition of 6 %
only in BxPC-3 cells. In an additional series of experi-
ments we also tested 1 mM ATP on YoPro-1 uptake,
but effects on pore formation were even smaller than
with 5 mM ATP and these are shown in Additional file
5: Figure S4. Interestingly, although 1–5 mM ATP did
not cause very pronounced pore-formation in PDAC
cells in given experimental conditions and A438079
had relatively small protective effects, the inhibitor
could nevertheless protected PDAC cells from cell
death during long-term incubation as shown in Fig. 5.
P2X7R increases cell migration and invasion
In order to determine effect of P2X7R on cell migration, a
scratch assay was used and cell proliferation was inhibited
Fig. 5 Effect of ATP and A438079, KN-62 on BrdU incorporation in Panc-1 and BxPC-3. Data show the BrdU incorporation in both cell lines after
60 h. The colored columns show the effect of different concentrations of added (exogenous) ATP (100 μM, 1 mM and 5 mM). The white columns
show the effect of ATP and control (no exogenous ATP added) in combination with the two inhibitors A438079 (10 μM) or KN-62 (100 nM), which
were added 1 h before ATP. The data were normalized to 1 % serum control (100). The graphs show data from three to six experiments (mean ± SEM);
where each run was carried out in triplicates. Significant differences P < 0.05 (*, #) and P < 0.001 (**) from the respective 1 % serum control (*, **) and
with/without inhibitor (#) are indicated
Fig. 4 BzATP has similar effects as ATP stimulation in PDAC and HPDE.
The BrdU incorporation data were normalized to 1 % serum control
(100), and all cell lines were normalized with respect to the control. The
black line and filled symbols show the effect of different concentration
of BzATP (10 μM, 100 μM and 1 mM) on BrdU incorporation in HPDE
cells after 60 h. The colour lines/symbols show the effect of BzATP on
the different PDAC cell lines. The graph shows data from three to six
experiments (mean ± SEM), each run was carried out in triplicates. At
100 μM BzATP, there were significant differences P < 0.05 (*) between
control and treatment in BxPC-3 and P < 0.001 (**) in HPDE and AsPC-1
cells. At 1 mM BzATP there was significant inhibition P < 0.001 (**) of
BrdU incorporation in all cell lines compared their respective controls
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by aphidicolin. Here we focus on Panc-1 cells as a repre-
sentative cell line that showed most significant effects of
AZ10606120 on cell proliferation (Fig. 3) and the fastest
migration among the PDAC cells (Additional file 6: Figure
S5). In the first set of experiments we used a mechanical
96-pin wound maker. As shown in Fig. 8a-b, the inhibitor
AZ10606120 (10 μM) did not show any effect on Panc-1
cells migration under these experimental conditions. We
reasoned that the scratch procedure caused cells damage
and ATP release that would obscure a possible effect of
P2X7R on migration, because there might be other P2 re-
ceptors that contribute to cell migration as shown in stud-
ies on other cells [42, 43]. Therefore, we used another
more gentle method, where the wound was created by
removal of a silicone insert and the results are shown
in Fig. 8c-d-e and Additional files 7 and 8. With this
new protocol it was possible to detect that AZ10606120
caused a significant, about 30 % reduction in Panc-1
migration compared to the control.
In order to evaluate whether the effect of P2X7R on
PDAC cells migration was associated with invasion, i.e.
the ability to degrade the ECM, a classical trans-well inva-
sion assay was performed with Panc-1 cells (Fig. 9). Cells
were incubated for 24 h with AZ10606120 (10 μM),
BzATP (10 μM) and ATP (100 μM). Results in Fig. 9 show
that the inhibitor caused about 20 % reduction in Panc-1
cell invasion compared to the control. BzATP and ATP
stimulation increased cell migration by about 27 % and
55 %, respectively.
Discussion
This study shows that pancreatic ductal adenocarcinoma
cells express P2X7 receptors, which regulate PDAC cell
behavior with respect to cell proliferation and cell death,
as well as in cell migration and invasion.
P2X7R is expressed in pancreatic cells of ductal ori-
gin at the mRNA and protein levels (Figs. 1 and 2).
Interestingly, rodent pancreatic acinar cells do not
seem to express mRNA for P2X7R [30], although
recent studies in pancreatic cancer field implicate
transdifferentiation of acinar cells to duct cells as an
important process in PDAC development [44]. In pan-
creatic duct cells, mRNA for P2X7R has a lower expres-
sion in all PDAC cell lines compared to HPDE cells
(Fig. 1a), although we cannot be absolutely sure that
HPDE cells are a faithful representative of healthy pan-
creatic ducts. Similar lower expression of receptor tran-
scripts was found in uterine epithelial cancer compared
to healthy controls [45]. In contrast, a number of other
cancers types show increased mRNA levels for P2X7R
compared to the normal tissues [46, 47]. Importantly,
we find that the P2X7RA protein level was higher in
PDAC cell lines compared HPDE (Fig. 1b). The dis-
crepancy between mRNA and protein levels could be
due to the fact that we detected transcripts from several
isoforms (as it is impossible to design qPCR primers
specific only for the isoform A), but we quantified the
protein levels of the most easily detectable and studied
isoform A (and B).
A B
Fig. 6 Cell death in Panc-1 cells in the presence of 1 mM ATP. a. Caspase 3/7 activation was measured in control cells and after 20 h incubation
with 1 mM ATP, AZ10606120 (10 μM), combination of both, and AT101 (apoptosis inducer). The results were normalized to 1 % serum control
(1.0). The graph shows data from four experiments (mean ± SEM); each run was carried out in duplicates. Significant difference P < 0.001 (**) from
the respective 1 % serum control is indicated. b. Annexin V-488 (green) and propidium iodide (red) were added after 20 h incubation with 1 mM
ATP in 1 % of serum. Fluorescent and transmission images were taken immediately after 10 min of incubation with the apoptosis/necrosis
markers, without fixation. Images are representative from 3 independent experiments. All bars are 25 and 10 μm
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Fig. 7 (See legend on next page.)
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Although PDAC cells express other P2X and P2Y re-
ceptors (Additional file 1: Figure S1), we have several
lines of evidence to demonstrate remarkable functional-
ity of the P2X7 receptor. Stimulation with increasing ex-
ogenous ATP concentrations resulted in a reduction of
BrdU incorporations in all cell lines (Figs. 3 and 5), and
similar results were also obtained with stimulation with
BzATP (Fig. 4). BzATP is considered as the most potent
agonist for P2X7 receptors, although we cannot exclude
contributions from other P2 receptors, which are acti-
vated at lower ATP concentration, or that BzATP acti-
vates potentially other receptors (e.g. P2X1 and P2X4
[48]). Nevertheless, we interpret these data to indicate
the classical role of P2X7 receptor in cell death induced
by high ATP concentrations and will return to this topic
in more detail below. An additional argument for P2X7R
functionality is the effect of two specific receptor inhibi-
tors, AZ10606120 and A438079, which had different ef-
fects on PDAC behavior.
One of the best documented roles of P2X7R is pore
formation and apoptosis/cell death [49]. We found that
high concentrations of ATP caused pore formation in
PDAC cell lines, as assayed by YoPro-1 uptake (Fig. 7).
The competitive antagonist A438079, which is known to
inhibit pore formation, decreased YoPro-1 uptake in all
PDAC cell lines tested. This agrees with the P2X7
receptor-pore inhibitor characteristic of A438079 also
described in pancreatic stellate cells, HEK293 cells and
A375 human melanoma cells [17, 50, 51]. Although the
pore formation is modest with high concentrations of
ATP, as detected by the standard YoPro-1 analysis over
60 min, during long-term incubation with ATP, PDAC
cells died with signatures of necrosis (Fig. 6). This was
also reported for mesangial and SN4741 dopaminergic
cells [13, 14] . Interestingly, although the pore-inhibitor
A438079 had very modest effects on pore formation de-
tected over a short period of incubation, it protected the
cells from cell death during long-term incubation with
high ATP concentrations (Fig. 5). Similar protective ef-
fects of the inhibitor in cell survival was detected in pan-
creatic stellate cells [17].
Let us now focus on the effect of the allosteric inhibitor,
which, firstly, substantiated our arguments for functional-
ity of P2X7R, and, second, revealed the proliferative effects
of P2X7R. Thus, the specific allosteric inhibitor of P2X7R,
AZ10606120 [52, 53], significantly reduced BrdU incorp-
oration in PDAC cells (Fig. 3), which was not due to off-
target cytotoxic effects (Additional file 4: Figure S3). Ra-
ther, we propose that the inhibitor decreased cell prolifera-
tion and thus revealed the proliferative potential of the
P2X7 receptor over-expression in PDAC, confirming its
pro-cancerous role. In “control” HPDE cells, which ex-
press lower protein levels of isoform A, the inhibitor had
no effect with exogenous ATP addition. Notably in all cell
lines, AZ10606120 had inhibitory effects even without
added ATP, indicating that the over-expression and basal
or tonic activation of P2X7R contribute to the hyperproli-
ferative state of PDAC cells. Our findings that P2X7R is
not only involved in cell death, but also in proliferation of
cancer cells, are supported by studies on pancreatic stel-
late cells [17], on ovarian carcinoma cells [41] and also in
vivo melanoma and colorectal tumor growth [27]. Import-
antly, some studies already suggest that AZ10606120 can
be used to abolish the proliferative phenotype of P2X7R
and reduce tumor size induced by melanoma B16 cells
[27].
The two inhibitors A438079 and AZ10606120 had
seemingly opposite effects on BrdU incorporation in
PDAC cells, one being protective and the other being
detrimental. This helped to reveal the double role of
P2X7R—in cell proliferation and cell death, both of
which would occur in a population of cells. It is not
clarified at this stage what molecular mechanisms and/
or molecular partners interacting with the receptor
could explain these seemingly disparate effects on cell
survival.
In addition to cell proliferation, cancer cell migration
and invasion are important in cancer behaviour. Our
study shows that P2X7R is important in these two can-
cer hallmarks as the allosteric modulator AZ10606120
significantly reduces both PDAC cell migration (Fig. 8,
Additional files 7 and 8) and invasion (Fig. 9). P2X7R
also contributes to cancer cell migration and invasion as
demonstrated in other types of cancer [47], though also
other P2 receptors (e.g. P2Y2) contribute to cancer cell
migration and invasion [54–56].
Taken together, our results show that multiple func-
tions of PDAC cell lines are regulated by P2X7R: cell
(See figure on previous page.)
Fig. 7 ATP stimulates pore formation. Yo-Pro-1 (2.5 μM) uptake was monitored after stimulation with 5 mM ATP alone, and in combination
with a pre-inhibition (1 h) with AZ10606120 (10 μM) or A438079 (10 μM). Fluorescence of YoPro-1 (Ex. 490 nm/Em. 510 nm) was measured in
Panc-1 (a, b), AsPC-1 (c, d) and BxPC-3 (e, f). a, c, e. Fluorescence values taken every 10 min for 60 min and normalized to the average of
values before administration of ATP. Representative images of Yo-Pro-1 green fluorescence for control, 5 mM ATP and ionomycin stimulated
cells (used as control to check Yo-Pro-1 efficacy) are shown as inserts for each cell lines. Note that BxPC-3 and AsPC-1 cells are more affected
by ATP and ionomycin, compared to Panc-1 cells, which agrees with data in Fig. 3 and the fact that the pore inhibitor has greater effect. All
bars are 100 μm. b, d, f. Values of normalized fluorescence at 60 min. The lines and bargraphs show data of four experiments (mean ± SEM);
each run was carried out in triplicates. Significant differences P < 0.05 (*, #) and P < 0.001 (**, ##) from the respective control (#, ##) and with/
without inhibitor (*, **) are indicated
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Fig. 8 Effect of AZ10606120 on Panc-1 cells migration. Confluent Panc-1 cells, grown in 96-well plate were scratched with a 96-pin wound maker
and treated with or without AZ10606120 (10 μM). a. The graph shows the percentage of open wound. Pictures were taken every 2 h. Images
were analyzed with the IncuCyte software using the relative wound density option, which measures the density of the wound according to the
density of the cell region. b. Percentage of wound still open after 24 h with and without inhibitor. The graphs show data of five experiments
(mean ± SEM); each run was carried out in triplicates. c. Confluent Panc-1 cells, grown in the two chambers of an Ibidi silicon insert, were treated
with or without AZ10606120 (10 μM). Phase contrast pictures were taken every hour and representative original images are shown at 0, 12 and
24 h after insert removal. d. Percentage of wound still open every hour with and without AZ10606120 (10 μM). Significant difference P < 0.05 (*)
between control and inhibitor (d) is calculated on the slope of the curves. e. Percentage of wound still open after 24 h with and without inhibitor.
In each picture the area was measured and normalized with the respective one at 0 h. In every experiment images were taken and area measured
from three to seven fields. The graphs show data from three to five experiments (mean ± SEM). Significant difference calculated for wound open
after 24 h
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proliferation, cell migration and invasion, pore-formation
and cell death. In a complex tumor, cells can encounter
sites of lower and high ATP concentrations, e.g. at the
periphery of tumor and at the core necrotic part of the
tumor, respectively. Our results are in line with the model
presented by Roger et al. [57] and with the “run or die”
hypothesis in cancer, [6], in which cancer cells have a pro-
cancerous basal activity of P2X7R that leads to prolifera-
tion and migration/invasion. Sustained activation, with
high concentrations of exogenous ATP/BzATP, in a closed
system (like a microplate well), which can reproduce the
cancer necrotic core, leads to cancer cell death. In con-
trast, in an open system (like a Boyden chamber), which
can reproduce the edge of the tumor, cancer cells have the
possibility to “move”. ATP can be read like a stress signal
and consequently cancer cells can increase the P2X7-pro-
invasive phenotype and escape the harmful cancer micro-
environment and invade new places. However, further in-
vestigations are needed to clarify the role of P2X7R in a
complex solid tumor microenvironment, such as that of
pancreatic cancer, and importantly to explore the potential
interaction between P2X7R expressing cells—PDAC,
PSCs, and immune cells, and as a recent report also sug-
gests, cancer stem cells [58]. In order to develop drug
therapies, it will be important to resolve in which cell type
the P2X7R-related events dominate cancer progression, as
for example studied recently by Adinolfi et al. [59].
Conclusions
In conclusion, our study shows that at least two P2X7 re-
ceptor isoforms are expressed in PDAC and contributes to
the basic cancer cell behavior in proliferation as wells as
to cell death, and to cell migration and invasion. There-
fore, we propose that the receptor could be exploited as a
potential therapeutic target for treatment of pancreatic
cancer.
Methods
Cell cultures
Human pancreatic ductal adenocarcinoma cell lines were
purchased from ATTC (Manassas, VA, USA). AsPC-1
(CRL-1682) and BxPC-3 (CRL-1687) were grown in
RPMI-1640 medium, Capan-1 (HTB-79) in Iscove’s Modi-
fied DMEM (IMDM), Panc-1 (CRL-1469) in Dulbecco’s
Modified Eagles Medium (DMEM) and MiaPaCa-2 (CRL-
1420) in DMEM/Ham’s F12. Cell culture media contained
stable glutamine, 10 % (20 % for Capan-1) fetal bovine
serum (FBS) (PAA Laboratories; A15-151 Gold) plus
2.5 % of horse serum for MiaPaCa-2 (Biochrom), 100 U/
ml penicillin and 100 μg/ml streptomycin. The human
pancreatic duct epithelial cell line HPDE6-E6E7 (H6c7)
[60, 61], which we refer to as HPDE, was obtained from
Dr. Ming-Sound Tsao. HPDE cells were grown in KBM
Basal Medium (Lonza, CC-3101), which is part of the
KGM-Bullet Kit (Lonza, CC-3111). Cells were grown at
37 °C in a humidified atmosphere with 5 % CO2. All
standard chemicals were purchased from Sigma-Aldrich
unless otherwise stated.
RNA isolation, RT-PCR and real time PCR
Cells were cultured to confluence in a Petri dish and
then RNA was isolated with RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. DNase I,
Qiagen was used. The cDNA was synthesized using the
RevertAid First Strand cDNA synthesis kit (Fermentas).
For RT-PCR cDNA, Jumpstart Taq DNA, primers and
dNTP mix were used; the amplification parameters were
as follows: one cycle at 95 °C for 1 min, 45 cycles at 95 °
Fig. 9 Effect of AZ10606120, BzATP and ATP on Panc-1 cells invasion. a. Difference in Panc-1 cells invasion. Cells were treated with or without
AZ10606120 (10 μM), BzATP (10 μM) or ATP (100 μM). The PET membrane, 8.0 μm pore size, was coated with Geltrex Matrix. The number of migrated
cells after 24 h was normalized with the control. b. Representative images of migrated cells after 24 h, fixed in cold methanol and stained with Crystal
violet. All bars are 100 μm. The graph shows data from four experiments; each run was carried out in duplicates (mean ± SEM). Significant differences
P < 0.05 (*, #) from the control (#) and between BzATP and ATP (*) are indicated
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C for 20 s, 57 °C for 30 s, 72 °C for 1.15 min, one final
cycle at 72 °C for 5 min. The transcripts were run elec-
trophoretically in 1.2 % agarose gel. The real time PCR
reactions were run using Roche FastStart Universal
SYBR Green Master (ROX) with parameters as follows:
one cycle at 50 °C for 2 min and one cycle at 95 °C for
10 min followed by 40 amplification cycles at 95 °C for
15 s, 57 °C for 1 min, 72 °C for 1 min and at the end a dis-
sociation step at 95 °C for 15 s, 60 °C for 15 s, 95 °C for
15 s. Data were evaluated with SDS 2.4 software (Applied
Biosystems). Primers were designed using Primer-BLAST
(NCBI) and synthesized by TAG Copenhagen A/S, DK.
Three housekeeping genes that were found quite stable in
normal and cancerous pancreatic tissues [62] were used
for normalization: β-actin, β-glucuronidase (GUSB) and
glutaminyl-tRNA synthetase (QARS). The relative amount
of the target mRNA was calculated from a standard curve
constructed from the results of a serial dilution run on
each plate, using Pfaffl method [63].
Western blot
Cells were cultured to confluence in a Petri dish and
lysed by adding 5x diluted lysis buffer (50 mM Tris-base,
0.25 M NaCl, 10 mM EDTA, 0.5 % NP40, 1 % TritonX-
100, 4 mM NaF, pH 7.5) with 1x protease inhibitor. The
final lysate was centrifuged at 15,000 g at 4 °C for 15 min.
Protein concentration was estimated with a Coomassie
protein assay. Protein samples were reduced by heating at
98 °C for 10 min with 50 mM DTT. 50 μg of proteins
were loaded and run in 10 % polyacrylamide precast gels
(Invitrogen) and blotted to PVDF membranes (Invitro-
gen). Membranes were blocked with 5 % skim milk solu-
tion in TBS-Tween 0.1 % buffer for 1 h at room
temperature and incubated overnight at 4 °C with primary
antibodies against P2X7R extracellular loop (1:200 rabbit
polyclonal, Alomone, APR-008) and β-Actin (1:1000
mouse monoclonal C4, Santa Cruz, Sc-47778). Blots were
then incubated with appropriate HRP-conjugated anti-
bodies and developed with EZ-ECL (Biological Industries)
and visualized on Fusion FX (Vilber Lourmat) and band
intensity was calculated using Bio1D software.
Confocal fluorescence microscopy
Cells were grown on glass coverslip, and then fixed in
4 % paraformaldehyde for 15 min at room temperature.
Cells were treated with 0.1 M TRIS-glycine (pH 7.4) for
15 min; permeabilized 0.3 % Tween-20 and blocked with
5 % BSA for 30 min. Cells were incubated with antibody
against P2X7R extracellular loop (1:100 rabbit polyclonal,
Alomone, APR-008) overnight at 4 °C. Then preparations
were incubated with a secondary antibody conjugated to
Alexa 568. DAPI (Molecular Probes) was used for nuclear
staining. Fluorescence was examined with 40x 1.3 NA
objective in Leica SP 5X MP confocal laser scanning
microscope. Images and overlays were analyzed in Leica
LAS AF software.
Cell proliferation
Cells were plated in white, clear bottom 96-well plates.
ATP and 2′-3′-O-(4-benzoylbenzoyl)-ATP (BzATP)
were dissolved in media and the pH was adjusted to 7.4
with NaOH. The indicated concentrations of ATP or
BzATP were added with and without P2X7R inhibitors
(10 μM AZ 10606120, 10 μM A438079 and 100 nM
KN-62, Tocris) in 1 % serum media (0 % of serum for
the experiments with low ATP concentrations—from
0.5 μM to 10 μM). After 60 h of incubation at 37 °C in a
humidified atmosphere with 5 % CO2, cells were treated
according to the manufacturer’s instruction of the Roche
Cell Proliferation ELISA, BrdU chemiluminescence kit.
Luminescence was read in FLUOstar OPTIMA (BMG
Labtech).
Cell viability assays
To check the possible cytotoxicity of the inhibitor
AZ10606120 (10 μM), the cell viability, was determined
using Trypan blue exclusion. Panc-1 and BxPC-3 cells
were grown in 6-well plates in 1 % serum. After 20 h,
40 h and 60 h of incubation at 37 °C in a humidified at-
mosphere with 5 % CO2, cells were incubated 10 min
with Trypan blue. Bright field images were taken with
Leica DMI6000B microscope and 10x objective. In order
to determine the mode of two common cell deaths
(apoptosis, necrosis) two assays were used. For apop-
tosis, Panc-1 cells were plated in white 96-well plates
with clear bottom. ATP solution adjusted to pH 7.4 was
added in 1 % serum media for a final concentration of
1 mM. Apoptosis inducer AT101 [64] was used as a con-
trol. After 20 h of incubation, caspase 3/7 activation was
determined. Cells were treated according to the manu-
facturer’s instruction of the Promega Caspase-Glo® 3/7
Assay. Luminescence was read by FLUOstar OPTIMA.
For necrosis assay Panc-1 cells were grown in 35 mm
glass-bottom dishes, after 20 h of treatment with ATP
cells were incubated for 15 min with Annexin V-488 and
Propidium Iodide (PI) (Life Technologies). Pictures were
taken with 40x 1.3 NA objective in Leica SP 5X MP con-
focal laser scanning microscope, CLSM. Images and
overlays were analyzed in Leica LAS AF software.
Pore formation
Cells were plated in black 96-well plates with clear bot-
tom. When a confluence around 80–90 % was reached,
the media was changed to a physiological buffer (140 mM
NaCl, 10 mM HEPES, 1 mM MgCl2, 0.4 mM KH2PO4,
1.6 mM K2HPO4, 1.5 mM CaCl2) with 11.1 mM of glu-
cose for AsPc-1 and BxPC-3 and 25 mM for Panc-1. Cells
were incubated with AZ10606120 (10 μM) or A438079
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(10 μM) for 1 h. Then cells were incubated with Yo-Pro-1
Iodide (2.5 μM, Molecular Probes) for 15 min. ATP was
dissolved in a physiological buffer and the indicated con-
centrations were added. Ionomycin (5 μM) was added at
the end of each experiment. Fluorescence was read every
10 min by FLUOstar OPTIMA.
Wound healing assay
The scratch assay was performed in two different
methods. In the first method, cells were grown to conflu-
ence in 96-well Essen ImageLock plate, and then incu-
bated with 10 μM AZ10606120 for 1 h and 5 μM
aphidicolin (to stop proliferation). The wounds were made
simultaneously in all wells with a 96-pin WoundMaker
(Essen BioScience), washed with PBS and phase contrast
pictures were taken every 2 h for 24 h in the IncuCyte
ZOOM Kinetic Imaging System. Pictures were processed
with the IncuCyte software using the relative wound dens-
ity (%RWD) option, which measures the density of the
wound with respect to the density of the cell region. The
program uses the following formula: %RWD= 100 × w(t)
−w(0)/c(t) −w(t); where, w(t) is the density of wounded
area at time t and c(t) is the density of cell region at time t.
To avoid cells damage, a second method was used. Ibidi
biocompatible silicone culture-insert was stuck in the cen-
ter of a 35 mm Petri dish and cells were plated in the same
number in the two chambers. When the confluence was
reached, the insert was removed and afterwards media
with and without AZ10606120 (10 μM) was added. 10x
phase contrast pictures were taken every 1 h for 24 h in
the Nikon BioStation IM-Q that allowed a temperature-
and gas-controlled environment. Images were analyzed by
Nikon NIS-Elements AR 4.13.03 software.
Invasion assay
The inserts for 24-well plates (transparent PET mem-
brane, 8.0 μm pore size, Falcon) were coated with Geltrex
Matrix (Invitrogen). 30.000 Panc-1 cells with aphidicolin
(5 μM) and with/without AZ10606120 (10 μM), BzATP
(10 μM) and ATP (100 μM) were placed in the upper
chamber in 1 % of serum, and media with 10 % of serum
was added in the lower chamber. After 24 h incubation at
37 °C in a humidified atmosphere with 5 % CO2, cells
were fixed in cold methanol and stained with Crystal
Violet. Bright field images were taken with 10x objective
in Leica DMI6000B microscope. Cells were counted by
ImageJ, NIH.
Chemicals and statistics
All chemicals/kits were purchased from Sigma-Aldrich
unless otherwise stated. Data are shown as mean values
± standard error of mean (SEM) and n represents the
number of biological replicates. Statistical analysis on
data was performed by using Students t-test and One-
way Analysis of Variance (ANOVA) with Holm-Sidak
method using SigmaPlot 11.0. Data were analyzed in
Origin or Microsoft Excel.
Additional files
Additional file 1: Figure S1. Expression of P2X7R in PDACs and HPDE
cells. Real time PCR analysis of P2X and P2Y receptors expression in HPDE
and PDAC cells. The data were normalized with respect to the three
housekeeping genes: β-actin, β glucuronidase (GUSB) and glutaminyl-tRNA
synthetase (QARS) and expression in HPDE was set to be 1. The bargraph
shows data for four experiments (mean ± SEM). The relative amount of
mRNA was calculated from a standard curve run on each plate. Significant
difference of expression in PDAC in comparison to HPDE cells is indicated
P < 0.05 (*) and P < 0.001 (**). (PDF 201 kb)
Additional file 2: Table S1. Primers used for RT-PCR and Real Time PCR
on PDACs and HPDE (DOC 33 kb)
Additional file 3: Figure S2. Effect of low ATP concentrations on BrdU
incorporation in Panc-1 cells. The graph shows the effect of low
concentrations of added (exogenous) ATP (0.5 μM, 3 μM, 7 μM and
10 μM), or control (no exogenous ATP added), on BrdU incorporation in
Panc-1 cell line after 60 h. The results were normalized to 0 % serum
control (100). The graph shows data from four independent experiments
(mean ± SEM); where each run was carried out in triplicates. No significant
differences compared to the control were detected. (PDF 59 kb)
Additional file 4: Figure S3. Absence of cytotoxicity of AZ10606120 on
PDAC cells. Representative bright field images of A. Panc-1 and B. BxPC-3
at 20, 40 and 60 h incubation with AZ10606120 (10 μM) and control. Cells
were stained with Trypan Blue at the time points given above. In every
experiment pictures were taken from eight to twelve fields (n = 3). All
bars are 50 μm. (PDF 1214 kb)
Additional file 5: Figure S4. Pore formation with 1 mM ATP. Yo-Pro-1
(2.5 μM) uptake was monitored after stimulation 1 mM ATP alone, and in
combination with a pre-inhibition (1 h) with AZ10606120 (10 μM) or A438079
(10 μM). Fluorescence of YoPro-1 (Ex. 490 nm/Em. 510 nm) was measured in
Panc-1 (A, B), AsPC-1 (C, D) and BxPC-3 (E, F). A, C, E. Fluorescence values
taken every 10 min for 60 min and normalized to the average of values
before administration of ATP. B, D, F. Values of normalized fluorescence at
60 min. The lines and bars-graphs show data of four experiments (mean ±
SEM); each run was carried out in triplicates. Significant differences P < 0.05
(*, #) and P < 0.001 (##) from the respective control (#, ##) and with/without
inhibitor (*) are indicated. (PDF 551 kb)
Additional file 6: Figure S5. PDAC cells migration. Confluent Panc-1,
BxPC-3, AsPC-3 and MiaPaCa-2 cells, grown in 96-well plate were
scratched with a 96-pin wound maker. The graph shows the percentage
of closed wound. Pictures were taken every 2 h. Images were analyzed
with the IncuCyte software using the relative wound density option, which
measures the density of the wound according to the density of the cell
region. The graphs show data from three to six experiments (mean ± SEM);
each run was carried out in triplicates. Significant differences among cell
lines P < 0.05 (*) and P < 0.001 (**) are calculated on the slope of the curves.
(PDF 352 kb)
Additional file 7: Video S6. Migration of Panc-1 cells grown in the two
chambers of an Ibidi silicon insert. Phase contrast pictures were taken
every hour for 24 h. (MP4 3335 kb)
Additional file 8: Video S7. Migration of Panc-1 cells in presence of
AZ10606120 inhibitor. Phase contrast pictures were taken every hour for
24 h. (MP4 2735 kb)
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